Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Mallinckrodt
Baxter
McKinsey
McKesson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,913,768

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,913,768
Title: Sustained release delivery of amphetamine salts
Abstract:A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR.RTM. type pulsatile formulations.
Inventor(s): Couch; Richard A. (Bryn Mawr, PA), Burnside; Beth A. (Bethesda, MD), Chang; Rong-Kun (Rockville, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:10/353,073
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,913,768
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 6,913,768

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-001 Jun 20, 2017 RX Yes No   Start Trial   Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER   Start Trial
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-002 Jun 20, 2017 RX Yes No   Start Trial   Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER   Start Trial
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-003 Jun 20, 2017 RX Yes No   Start Trial   Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER   Start Trial
Shire Dev Llc MYDAYIS amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 022063-004 Jun 20, 2017 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,913,768

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2030   Start Trial
Austria 495731   Start Trial
Australia 2003272619   Start Trial
Brazil 0314486   Start Trial
Canada 2499546   Start Trial
China 1684668   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Colorcon
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.